Related by context. All words. (Click for frequent words.) 79 Phase Ib clinical 78 Phase Ib II 77 Phase Ib 77 Phase 2a trial 77 phase IIb 77 Phase 1a clinical 76 phase Ib 76 phase IIa clinical 76 phase IIb trial 76 phase IIa 76 Phase 1b trial 75 Phase #/#a 75 Phase IIa trial 75 phase IIb clinical 75 Phase 2b study 75 Phase 2b trial 75 pharmacokinetic PK study 75 Phase IIa clinical 75 INCB# [001] 75 Cloretazine ® 75 Phase #b/#a 75 Phase 1b 75 GLP toxicology studies 74 Phase IIIb clinical 74 alvespimycin 74 elotuzumab 74 Phase 2a clinical 74 phase IIb study 74 Phase IIb trials 74 ongoing Phase 1b 74 randomized controlled Phase 73 Phase IIb clinical trials 73 dose escalation Phase 73 Phase 2a 73 SUCCEED trial 73 Plicera 73 phase 2a 73 mertansine 73 Phase IIB 73 oral prodrug 73 Phase #b/#a trial 73 confirmatory Phase III 73 Phase 2a clinical trials 73 rALLy trial 73 Phase 1b clinical 73 Alocrest 73 dose escalation trial 72 CR# vcMMAE 72 oral ridaforolimus 72 GAMMAGARD 72 HuMax EGFr 72 IMA# 72 Phase Ia 72 JAK inhibitor 72 GALNS 72 Sym# 72 HuMax CD4 72 histone deacetylase HDAC inhibitor 72 IIa trial 72 IND submission 72 ATL# [001] 72 Annamycin 72 Phase IIa 72 PDE4 inhibitor 72 pomalidomide 72 BLA filing 72 YONDELIS 72 Androxal TM 72 phase Ib clinical 72 cannabinor 72 vidofludimus 72 neratinib 72 ganetespib 71 pharmacokinetic PK 71 TBC# 71 NP2 Enkephalin 71 XmAb# 71 registrational trial 71 forodesine 71 ruxolitinib 71 Alzhemed TM 71 HGS# 71 ELACYT 71 Traficet EN 71 tanespimycin 71 Phase III randomized controlled 71 CEQ# 71 tezampanel 71 multicenter Phase 71 CRLX# 71 PSMA ADC 71 Aurexis 71 Tesetaxel 71 BAY #-# 71 enzastaurin 71 PRT# 71 huC# DM4 71 Phase 1a 71 Zenvia ™ 71 dirucotide 71 selective androgen receptor modulator 71 anticancer compound 71 Dacogen injection 71 huN# DM1 71 trastuzumab DM1 T DM1 71 Phase #b/#a clinical 71 fidaxomicin Phase 3 71 PRECISE trial 71 adecatumumab 71 BRIM3 71 multicenter Phase II 70 pivotal bioequivalence 70 Xanafide 70 preclinical efficacy 70 Phase 2b clinical 70 Zenvia Phase III 70 FOLOTYN ® 70 CLORETAZINE TM VNP#M 70 deforolimus 70 BRIM2 70 TACI Ig 70 Phase 1b clinical trials 70 lorvotuzumab mertansine 70 PROSTVAC TM 70 dose escalation clinical 70 ADVANCE PD 70 Phase IIb trial 70 IMGN# 70 CoFactor 70 fosbretabulin 70 Cloretazine 70 Aflibercept 70 IL# PE#QQR 70 KNS # 70 elacytarabine 70 Phenoptin 70 CRMD# 70 seliciclib CYC# 70 ENDEAVOR IV 70 Bicifadine 70 HGS ETR1 70 PDX pralatrexate 70 MAGE A3 ASCI 70 registrational 70 PXD# 70 PEG SN# 70 trodusquemine 70 Phase IIa trials 70 Personalized Immunotherapy 70 NVA# 70 viral kinetic 70 PHX# 70 Phase III psoriasis 70 relapsed refractory multiple myeloma 70 bardoxolone 70 Cloretazine R VNP#M 70 dose cohort 70 axitinib 70 EOquin TM 70 randomized Phase 2b 70 Phase IIb 70 MEND CABG 70 zanolimumab 70 Panzem R NCD 70 Phase III 70 AZILECT R 70 budesonide foam 70 DermaVir Patch 70 Triolex 70 AZILECT ® 70 Azedra 70 Spiegelmer ® 70 preclinically 70 OvaRex ® MAb 69 JZP 69 Aplidin 69 torezolid phosphate 69 clinical pharmacology studies 69 Amrubicin 69 Phase III clinical 69 intranasal formulation 69 solithromycin 69 Archexin 69 vascular disrupting agent 69 Trofex 69 velafermin 69 CCX# 69 methylnaltrexone 69 Phase III Pivotal 69 Phase IIa clinical trials 69 OncoGel 69 Azedra TM 69 Phase #/#a trial 69 randomized Phase IIb 69 generation purine nucleoside 69 ADAGIO study 69 teriflunomide 69 rALLy clinical trial 69 VNP#M 69 perifosine KRX 69 Omacetaxine 69 BAL# [002] 69 initiate Phase 1b 69 pharmacodynamic PD 69 efficacy endpoint 69 pertuzumab 69 ENMD # 69 investigational humanized monoclonal antibody 69 triphendiol 69 PNP inhibitor 69 orally bioavailable 69 TMC# [002] 69 Phase Ib clinical trials 69 docetaxel Taxotere R 69 PSN# [002] 69 BCX# 69 Aurora kinase inhibitor 69 lintuzumab 69 R#/MEM # 69 Factor VIIa 69 AP# [003] 69 Tarceva TM 69 AVADO 69 Mipomersen 69 Guanilib 69 GRN# 69 liposomal formulation 69 Fodosine 69 phase IIb III 69 virus HCV protease inhibitor 69 OvaRex R 69 nonclinical studies 69 Elagolix 69 Pimavanserin 69 EOquin 69 SAR# [004] 69 midstage clinical 69 NGX# 69 Phase IIb clinical 68 NOX E# 68 randomized Phase III 68 PEG PAL 68 antibody MAb 68 brivaracetam 68 dosing cohort 68 MGd 68 Ocrelizumab 68 Corlux 68 Troxatyl 68 Phase III Clinical Trial 68 davunetide intranasal AL 68 AEG# 68 MEND CABG II 68 omacetaxine mepesuccinate 68 non nucleoside inhibitor 68 cangrelor 68 investigational antiplatelet agent 68 EGS# 68 ILLUMINATE 68 TLK# 68 RGB # 68 Phase IIb III 68 JAK2 inhibitor 68 romidepsin novel 68 Ozarelix 68 sNDA submission 68 riociguat 68 evaluating tivozanib 68 Tezampanel 68 ularitide 68 Urocidin 68 EndoTAG TM -1 68 CBLC# 68 lomitapide 68 tiapamil 68 leading oral taxane 68 Telatinib 68 midstage trials 68 INCB# [003] 68 eniluracil 68 Phase 2b clinical trials 68 Quinamed 68 Prostate AdenoCarcinoma Treatment 68 KRN# 68 placebo controlled Phase 68 PFO migraine 68 USL# 68 reslizumab 68 trastuzumab emtansine T DM1 68 phase IIIb 68 INCB# [002] 68 Hedgehog antagonist 68 EXPAREL ™ 68 LymphoStat B TM 68 OXi# 68 ONCONASE R 68 ABSORB trial 68 ORAL Sync 68 refractory chronic lymphocytic 68 PD LID 68 Velcade bortezomib 68 MERLIN TIMI 68 opioid induced bowel dysfunction 68 UPLYSO 68 pivotal Phase III 68 RhuDex ® 68 Safinamide 68 Fx #A 68 entinostat 68 trastuzumab DM1 68 Cimzia ® certolizumab pegol 68 AMPAKINE CX# 68 PANVAC VF 68 Phase III confirmatory 68 APTIVUS 68 Chemophase 68 Zybrestat 68 lumiliximab 68 receptor tyrosine kinase inhibitor 68 ILUVIEN ® 68 APEX PD 68 HspE7 68 DXL# 68 Fibrillex TM 68 Zenvia TM 68 oral methylnaltrexone 68 obatoclax 68 Anavex #-# 68 alemtuzumab Campath 68 tezampanel NGX# 67 metastatic hormone refractory 67 assessing T DM1 67 AeroLEF TM 67 JAK1 67 GLYX 67 ponatinib 67 galiximab 67 ocular formulation 67 PS# DARA 67 Urocortin 2 67 SinuNase ™ 67 Pivotal Phase III 67 Proxinium TM 67 PF # [001] 67 CHAMPION PCI 67 adipiplon 67 Carfilzomib 67 viral kinetics 67 MKC# MKC# PP 67 QLT# 67 HCD# [002] 67 TG# [003] 67 Degarelix 67 baminercept 67 OncoVEX GM CSF 67 Phase lll 67 HuMax CD# 67 maturation inhibitor 67 miconazole Lauriad ® 67 tolevamer 67 ozarelix 67 radiation sensitizer 67 confirmatory Phase 3 67 Panzem NCD 67 HGS ETR2 67 farletuzumab 67 dose cohorts 67 Aryplase 67 Diabetic Macular Edema DME 67 eprotirome 67 PS# [001] 67 generation URAT1 inhibitor 67 TRO# 67 bevirimat Study 67 orally dosed 67 pharmacokinetics PK 67 Onrigin 67 ProSavin 67 velafermin belinostat 67 TRX1 67 Omnitarg 67 RAV# 67 sitaxsentan 67 investigational pan BCR 67 Virulizin ® 67 Zemplar Capsules 67 PRTX 67 RSD# oral 67 ospemifene 67 EDEMA3 trial 67 DDP# 67 OMP #M# 67 Allovectin 7 ® 67 Phase III ALLEGRO 67 Ceflatonin 67 ALN TTR# 67 optimal dosing regimens 67 BLA submission 67 depsipeptide 67 alvimopan 67 PA# [002] 67 aclidinium 67 LE SN# 67 radezolid 67 Allovectin 7 67 LUMINATE 67 TELINTRA 67 Nanobody 67 ToGA 67 desvenlafaxine succinate 67 pharmacodynamic properties 67 unblind 67 romidepsin 67 relapsed MM 67 PrevOnco 67 metaglidasen 67 lintuzumab SGN 67 beta 1a 67 Aurora kinase inhibitors 67 MEK inhibitor 67 immatics 67 Dyloject TM 67 SAR# [002] 67 Clonicel 67 Azedra ™ 67 REVIVE Diabetes 67 Tarvacin TM 67 HQK 67 acyclovir Lauriad R 67 SABCS 67 STRIDE PD 67 favorable pharmacokinetic profile 67 AQ4N 67 GW# [003] 67 oral picoplatin 67 relapsed multiple myeloma 67 placebo controlled Phase III 67 Solorel 67 R# #mg BID 67 Phase Ib IIa 67 multicenter randomized placebo controlled 67 Capesaris 67 initiate Phase IIb 67 Pafuramidine 67 Genz # 67 urocortin 2 67 volociximab 67 cancer neuroendocrine tumor 67 RH1 67 R roscovitine 67 Q#IR 67 HCV SPRINT 67 placebo controlled clinical 67 CAMMS# 67 rindopepimut 67 PROVENGE sipuleucel T 67 R#/MEM 67 IMC A# 67 Aplidin R 67 investigational HCV polymerase 67 MAA submission 67 GAP #B# 67 dacetuzumab 67 clevidipine 66 Dapagliflozin 66 Ophena TM 66 DEB# 66 IRX 2 66 dasatinib Sprycel ® 66 CD# antibody [001] 66 ATL# [002] 66 Phase 1b dose escalation 66 SNT MC# 66 Phase III Clinical Trials 66 maximally tolerated dose 66 sapacitabine 66 Dacogen decitabine 66 ALGRX 66 orally administered inhibitor 66 PREOS R 66 multiple ascending dose 66 rNAPc2 66 subcutaneous formulation 66 tubulin inhibitor 66 Allovectin 7 R 66 multicentre randomized 66 octreotide implant 66 MOZOBIL 66 candidate CRLX# 66 mg/m2 cohort 66 Altastaph 66 VITAL Trial 66 delafloxacin 66 GRNVAC1 66 targeted radiotherapeutic 66 PNT# 66 Pivotal Trial 66 multicenter randomized Phase 66 Panzem R 66 ritonavir boosted danoprevir 66 ATL/TV# 66 dose escalation phase 66 NO# [002] 66 SYMMETRY trial 66 preclinical pharmacokinetic 66 IMPACT IMmunotherapy 66 Zingo TM 66 novel oral anticoagulant 66 immunomodulatory therapy 66 ACAPODENE 66 PrevOnco ™ 66 initiate Phase 2b 66 OncoVEX 66 Cleviprex TM clevidipine 66 mapatumumab 66 ROCKET AF 66 unblinding 66 CA9 SCAN 66 Kahalalide F 66 MAP# 66 Phase II 66 CLIRS trial 66 rilonacept 66 severe hypercholesterolemia 66 MAXY alpha 66 Symadex 66 CLARITY study 66 Initiate Phase 66 cariprazine 66 MYDICAR 66 compound INCB# 66 multicenter Phase III 66 bendamustine 66 Hsp# Inhibitor 66 refractory multiple myeloma 66 PEG IFN 66 refractory CLL 66 T Pred 66 DASISION 66 Vitaxin 66 Initiated Phase 66 sunitinib malate 66 APEX AMI trial 66 CTAP# Capsules 66 Genta Incorporated OTCBB GETA 66 AAG geldanamycin analog 66 Vicinium TM 66 prucalopride 66 WILEX 66 dosing cohorts 66 ANTEGREN 66 oxymorphone ER 66 Phase 2b monotherapy 66 severe gastroparesis 66 LCP AtorFen 66 Matrix Phase 2b 66 ELND# 66 immunotherapeutic agent 66 omega interferon 66 EDEMA3 66 OMAPRO 66 glucokinase activator 66 blinded randomized placebo controlled 66 ZD# [001] 66 otelixizumab 66 Glufosfamide 66 Phase III trials 66 ARIKACE ™ 66 crizotinib PF # 66 oral rivaroxaban 66 AzaSite Plus 66 TASKi2 66 Phase 2b kidney transplant 66 investigational hepatitis C 66 dose escalation 66 including eniluracil ADH 66 Exherin TM 66 Alvesco R 66 MLN# 66 atacicept 66 bortezomib Velcade 66 NXL# 66 Veronate 66 multicenter phase 66 RIGScan CR 66 cediranib 66 Phase 2b 66 PROSTVAC ® 66 ASONEP 66 Hedgehog pathway inhibitor 66 GLPG# 66 dexanabinol 66 Phase 2b Clinical Trial 66 PMA submission 66 pralatrexate 66 Laquinimod 66 relapsed MCL 66 Ampligen ® 66 BEMA TM Fentanyl 66 PEARL SC 66 BNC# 66 Blinatumomab 66 MNTX 66 Nuvion 66 CB2 selective receptor agonist 66 Genasense ® oblimersen 66 ribavirin RBV 66 ISIS # 66 OHR/AVR# 66 ZEVALIN ® 66 Reverset 66 metastatic castration resistant 66 initiated Phase Ib 66 eltrombopag 66 Novolimus 66 histamine dihydrochloride 66 CIMZIA ™ 66 Phase III ADT 66 HER2 positive metastatic breast 66 SinuNase 66 posaconazole 66 BiTE R 66 IAP inhibitors 66 milatuzumab 66 nab paclitaxel 66 PRIMO CABG 66 corticosteroid dexamethasone 66 telomerase therapeutic 66 proteasome inhibitor 66 investigational oral hepatitis C 66 BrachySil TM 66 inhaled AAT 66 Oral NKTR 66 TKB# 66 Iluvien ® 65 CA4P 65 polymerase inhibitor 65 teduglutide 65 investigational compound 65 clinicaltrials 65 Ketotransdel 65 PROMACTA 65 PRX # 65 refractory cutaneous T 65 Phase IIb Trial 65 FDA Approvable Letter 65 belinostat 65 LUX Lung 65 pharmacokinetic studies 65 pradefovir 65 pharmacokinetic PK profile 65 BCR ABL inhibitor 65 IND enabling 65 herpetic keratitis 65 iclaprim 65 Ambrisentan 65 AeroLEF 65 dose escalation study 65 Phase IIb Clinical Trial 65 regorafenib 65 nucleotide analog 65 HCV protease inhibitor 65 Bezielle 65 sorafenib Nexavar 65 SPIRIT FIRST 65 pharmacokinetic pharmacodynamic 65 BEMA Buprenorphine 65 Ophena 65 ulimorelin 65 recurrent GBM 65 pharmacodynamic effects 65 Octreolin 65 preclinical toxicology 65 IIb clinical trial 65 ALN TTR 65 Pertuzumab 65 Prodarsan ® 65 Oglemilast 65 AKT inhibitor 65 CUSTOM III 65 Genasense ® 65 LEP ETU 65 TPI ASM8 65 VitiGam 65 TG# [001] 65 generation NNRTI 65 dexpramipexole 65 TRANSDUR Bupivacaine 65 oral deforolimus 65 Phase III HEAT 65 mGluR5 negative 65 rPA anthrax vaccine 65 bicifadine 65 Kamada AAT 65 Clavis Pharma 65 SPRYCEL ® 65 DCCR 65 cell lymphoma CTCL 65 IAP inhibitor 65 Acute Ischemic Stroke 65 ChronVac C ® 65 Augment Injectable 65 BEMA Granisetron 65 TELCYTA 65 Xibrom TM 65 CCR5 mAb 65 non nucleoside HCV 65 CD# CEA 65 RSD# 65 indibulin 65 ORMD 65 CINTREDEKIN BESUDOTOX 65 NASDAQ CXSP announced 65 Phase IIIb study 65 NADiA ProsVue 65 relapsing remitting multiple sclerosis 65 Oncotype DX colon cancer 65 Onalta ™ 65 tesmilifene 65 Lu AA# 65 OMNARIS Nasal Spray 65 treatment naive genotype 65 Sapacitabine 65 liprotamase 65 octreotide acetate 65 LB# [003] 65 IMC #B 65 cetuximab Erbitux R 65 Phase IIIb 65 selective modulator 65 thalidomide Thalomid 65 cystinosis patients 65 MoxDuo IR 65 ZYBRESTAT TM 65 DAVANAT 65 AEGR 65 ZYBRESTAT 65 Elocalcitol 65 CYT# 65 adecatumumab MT# 65 metastatic CRC 65 NeuVax 65 Proellex TM 65 BioNumerik 65 REG1 65 nalbuphine ER 65 SCH # 65 Viramidine 65 TG MV 65 ofatumumab HuMax CD# 65 LAF# 65 GSK# [001] 65 Civacir 65 Shigamabs ® 65 Tyrima 65 CXA 65 plasma kallikrein inhibitor 65 Randomized Phase 65 formal pharmacokinetic PK 65 MGCD# [001] 65 ASCO abstract 65 ara C 65 oral FTY# 65 Deforolimus 65 GMX# 65 Lisofylline LSF 65 PI3K/Akt pathway inhibitor 65 CG# [003] 65 trial evaluating PRX# 65 DR Cysteamine 65 REG2 65 LibiGel ® 65 Orazol 65 satraplatin Phase 65 Enzastaurin 65 inhibitor RG# 65 CYT# potent vascular disrupting 65 subcutaneously administered 65 JVRS 65 UVIDEM 65 ARIKACE 65 Rigel R# 65 Diamyd ® 65 Lovaxin C 65 CCR5 antagonist 65 Pharmacokinetics PK 65 bepotastine besilate nasal spray 65 Dose escalation 65 INT# [002] 65 gemcitabine Gemzar ® 65 European Sepsis Trial 65 Triapine R 65 lexidronam injection 65 Apoptone 65 ThermoDox R 65 VELCADE melphalan 65 interferon gamma 1b 65 PEGylated interferon beta 1a 65 evaluating satraplatin 65 JAK inhibitors 65 GSK# [002] 65 talactoferrin 65 Romidepsin 65 Xcytrin R 65 CIMZIA TM 65 initiate Phase Ib 65 leukemia AML 65 PEGylated interferon 65 alemtuzumab MS 65 bosutinib 65 lucinactant 65 BIBW 65 CytoFabTM 65 nanopharmaceutical 65 lesinurad 65 Neuradiab 65 BrachySil 65 Clinical Trial Results 65 StemEx R 65 AMD# [003] 65 generation Hsp# inhibitor 65 GRAVITAS trial 65 ocrelizumab 65 Onconase 65 pan HDAC inhibitor 65 TMC# C# 65 Pivotal Phase 65 ExTRACT TIMI 65 CYC# 65 aurora kinase 65 CIP TRAMADOL ER 65 BLOOM DM 65 LEVADEX ™ 65 ALN VSP Phase 65 tramiprosate Alzhemed TM 65 sulodexide 65 GV# [001] 65 novel histone deacetylase 65 dextromethorphan quinidine 65 Nexavar sorafenib 65 double blinded placebo 65 SUTENT ® 65 olaparib 65 Lenocta 65 Alinia 65 non nucleoside 65 glufosfamide 65 Asentar 65 initiate Phase IIa 65 multi kinase inhibitor 65 Firazyr 65 pharmacodynamic profile 65 generation antisense inhibitor 65 ZYBRESTAT fosbretabulin 65 sipuleucel T 65 ITAX 65 PREOS 65 celgosivir 65 MT#/MEDI-# 65 Phase III pivotal 65 Clolar ® 65 PEGylated Fab fragment 65 mRCC 65 Zemiva ™ 65 Huntexil 65 ORENCIA ® 65 Tasimelteon 65 Vicriviroc 65 Multiple Ascending Dose 65 Ceflatonin R 65 nucleoside analog 64 CRx 64 PF # [002] 64 docetaxel Taxotere ® 64 ThGRF 64 incyclinide 64 Vernakalant 64 Daclizumab 64 NEBIDO 64 bazedoxifene conjugated estrogens 64 ofatumumab 64 mitogen activated ERK kinase 64 ancrod 64 novel VDA molecule 64 paclitaxel Taxol ® 64 Nasulin 64 ALN PCS 64 Marqibo 64 TRC# 64 Tocosol Paclitaxel 64 eliglustat tartrate 64 Soliris eculizumab 64 paclitaxel Taxol R 64 IIa trials 64 II Clinical Trial 64 TOLAMBA 64 Golimumab 64 telaprevir VX 64 Phase 2a Study 64 systemically administered 64 Saforis 64 Nasdaq IDRA 64 Cimzia TM 64 Solorel TM 64 pafuramidine 64 Phase 2b Trial 64 OMNARIS HFA 64 Phase III Trial 64 MDV# 64 AIMM trial 64 Interferon alpha 64 inhaled formulation 64 Targretin capsules 64 epothilone 64 ixabepilone 64 Pazopanib 64 refractory AML 64 Tanespimycin 64 GFT# 64 Fibrin Pad 64 Zerenex 64 recurrent glioblastoma multiforme 64 Aloxi injection 64 EDEMA4 64 HepaSphere 64 Desmoteplase 64 Evoltra TM 64 RE LY ® 64 REG1 Anticoagulation System 64 hyaluronidase enzyme 64 amrubicin 64 vinca alkaloid 64 prospectively defined 64 AZD# 64 cilengitide 64 Lodotra TM 64 palifosfamide Zymafos TM 64 Phase #/#a clinical 64 Loramyc R 64 vorinostat 64 ChronVac C R 64 Icatibant 64 MoxDuo 64 rALLy 64 isatoribine 64 sargramostim 64 talabostat 64 muraglitazar 64 Presents Preclinical 64 Vilazodone 64 Amigal 64 Telintra 64 systemic RNAi therapeutic 64 Ridaforolimus 64 EP #R 64 diabetic neuropathic pain 64 SYN# 64 ganaxolone 64 dalbavancin 64 Elvitegravir 64 glatiramer acetate 64 eosinophilic asthma 64 MEK inhibitor RDEA# 64 Dasatinib 64 MBP# [001] 64 telaprevir dosing 64 Triapine 64 ZK EPO 64 Darusentan 64 long acting muscarinic 64 Iloperidone 64 lead Aganocide compound 64 HCV RESPOND 2 64 daptomycin 64 Dalbavancin 64 oral treprostinil 64 Telavancin 64 EVIZON 64 Phase III metastatic melanoma 64 Initiates Clinical 64 mGluR5 NAM 64 Phase Ib Clinical Trial 64 preclinical studies 64 mipomersen 64 IPL# 64 vemurafenib 64 trastuzumab Herceptin R 64 initiated Phase 1b 64 Arikace 64 ACCLAIM II 64 CD3 monoclonal antibody 64 XL# XL# XL# 64 Voreloxin 64 cMET 64 Shigamabs R 64 Trofex TM 64 MabCampath 64 Dacogen TM 64 subcutaneous PRO